Ariad Pharmaceuticals, Inc. Reports Second Quarter 2013 Financial Results and Development Progress

Published: Aug 07, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2013, including revenue from Iclusig® (ponatinib), which is approved by the U.S. Food & Drug Administration and the European Commission. The Company also provided an update on corporate developments.

“Our second-quarter results demonstrate strong growth of Iclusig sales in the U.S.,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news